<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02043730</url>
  </required_header>
  <id_info>
    <org_study_id>2013-002973-23</org_study_id>
    <nct_id>NCT02043730</nct_id>
  </id_info>
  <brief_title>Abraxane and Gemcitabine Versus Gemcitabine Alone in Locally Advanced Unresectable Pancreatic Cancer.</brief_title>
  <acronym>GAP</acronym>
  <official_title>A Phase II Randomized Trial Comparing a Combination of Abraxane and Gemcitabine Versus Gemcitabine Alone as First Line Treatment in Locally Advanced Unresectable Pancreatic Cancer. GAP (Gemcitabine Abraxane Pancreas) Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Unit√† Sperimentazioni cliniche</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Istituto Nazionale Tumori di Napoli</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Gruppo Italiano per lo studio dei Carcinomi dell'Apparato Digerente</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Pancreatic cancer is the fourth cause of cancer mortality: there are different treatment
      approaches to locally advanced pancreatic cancer management.

      Generally, gemcitabine alone is considered a reasonable approach for advanced pancreatic
      cancer patients but we need a chemotherapeutic regimen able to prevent as much as possible a
      progression of the disease. Nab-paclitaxel (Abraxane) recently demonstrated an interesting
      activity profile in advanced pancreatic cancer. A combination of Nab-paclitaxel and
      gemcitabine has been demonstrated superior to gemcitabine alone in metastatic patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Study population: Locally advanced unresectable pancreatic cancer patients

      Elegibility criteria:

        -  Written informed consent

        -  Age &gt;18 &lt; 75 years

        -  Histologically/cytologically confirmed locally advanced, unresectable pancreatic cancer

        -  At least one lesion measurable with CT or MRI scan

        -  Performance Status (ECOG) 0-1 at study entry

        -  Life expectancy of at least 3 months

        -  Adequate marrow, liver and renal function

        -  Effective contraception if the risk of conception exists (in the Informed Consent for
           the patients the descriptions of possible contraceptives is reported
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>January 2014</start_date>
  <completion_date type="Anticipated">January 2017</completion_date>
  <primary_completion_date type="Anticipated">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Participant)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Progression Rate</measure>
    <time_frame>progression rate is evaluated after 3 cycles of chemotherapy</time_frame>
    <description>Assuming an expected progression rate in the control arm of 40% and an auspicated progression rate in the experimental arm of 20%,with one-tailed alpha=0.05, 80% power, 124 patients are required for the final analysis</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quality of Response</measure>
    <time_frame>Response to treatment is evaluated according to the RECIST criteria at the end of chemotherapy</time_frame>
    <description>All patients must be considered in response analysis, including those who discontinue treatment or who die for any reason prior to response evaluations</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxicity</measure>
    <time_frame>every 3 cycles of chemotherapy</time_frame>
    <description>Treatment-emergent adverse events, drug-related adverse events and safety laboratory parameters will be analysed by treatment groups and CTCAE grade</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression Free Survival</measure>
    <time_frame>time from the start of the treatment until PD or death</time_frame>
    <description>Progression free survival time will be defined as the time from randomization until the date of first observed disease progression (radiological or clinical, whichever is earlier) or death due to any cause, if death occurs before progression is documented.
Patients who did not progress will be censored at the last date they were known to be alive.
Patients who died of disease and for whom a date of progression is not available will be considered to have progressed on the day of their death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival</measure>
    <time_frame>the time from randomization to the date of death</time_frame>
    <description>Overall survival time will be defined as the time from randomization to the date of death. If the subject has not died, survival will be censored on the last date the subject was known to be alive (last date of follow up).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">124</enrollment>
  <condition>Pancreatic Cancer Stage II</condition>
  <arm_group>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>ARM A: nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>ARM B: Gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Nab-paclitaxel and Gemcitabine</intervention_name>
    <description>Chemotherapy will consist of nab-paclitaxel 125 mg/mq over 30 min and gemcitabine 1000 mg/mq weekly on days 1, 8 and 15 of a 28-day cycle</description>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <other_name>abraxane</other_name>
    <other_name>gemzar</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Gemcitabine</intervention_name>
    <description>gemcitabine 1000 mg/mq over 30 minutes on days 1, 8 and 15 of a 28-day cycle.</description>
    <arm_group_label>nab-paclitaxel and gemcitabine</arm_group_label>
    <arm_group_label>Gemcitabine</arm_group_label>
    <other_name>gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Written informed consent

          -  Age &gt;18 &lt; 75 years

          -  Histologically/cytologically confirmed locally advanced, unresectable pancreatic
             cancer

          -  At least one lesion measurable with CT or MRI scan

          -  Performance Status (ECOG) 0-1 at study entry

          -  Life expectancy of at least 3 months

          -  Adequate marrow, liver and renal function

          -  Effective contraception if the risk of conception exists (in the Informed Consent for
             the patients the descriptions of possible contraceptives is reported)

        Exclusion Criteria:

          -  Previous chemotherapy or radiotherapy for pancreatic cancer

          -  Severe cardiovascular disease

          -  Thrombotic or embolic events

          -  Acute or subacute intestinal occlusion or history of inflammatory bowel disease

          -  Known hypersensitivity to study drug

          -  Known drugs or alcohol abuse

          -  Pregnant or breastfeeding women

          -  Previous or concurrent malignancy; except for basal or squamous cell skin cancer
             and/or in situ carcinoma of the cervix, or other solid tumors treated curatively and
             with evidence of no recurrence for at least 5 years prior to randomization

          -  Unable to sign informed consent
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stefano Cascinu, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>GISCAD Foundation</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Silvia Rota, DM</last_name>
    <phone>+39 0331 490052</phone>
    <email>centrotrialgiscad@yahoo.it</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marilina Piccirillo, DM</last_name>
    <phone>+39 081 5903571</phone>
    <email>marilina.piccirillo@usc-intnapoli.net</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>A.O. Universitaria Ospedali Riuniti</name>
      <address>
        <city>Ancona</city>
        <state>AN</state>
        <zip>60100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rossana Berardi, MD</last_name>
      <phone>+39 071 5963</phone>
      <phone_ext>834</phone_ext>
      <email>r.berardi@univpm.it</email>
    </contact>
    <investigator>
      <last_name>Rossana Berardi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Istituto Tumori Giovanni Paolo II</name>
      <address>
        <city>Bari</city>
        <state>BA</state>
        <zip>70124</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Treviglio-Caravaggio, P.le Ospedale n1</name>
      <address>
        <city>Treviglio</city>
        <state>Bergamo</state>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Humanitas Gavazzeni</name>
      <address>
        <city>Bergamo</city>
        <state>BG</state>
        <zip>24125</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale G.Rummo</name>
      <address>
        <city>Benevento</city>
        <state>BN</state>
        <zip>82100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>ASDAA Bolzano</name>
      <address>
        <city>Bolzano</city>
        <state>BZ</state>
        <zip>39100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Claudio Graiff, MD</last_name>
      <phone>+39 0471 908952</phone>
    </contact>
    <investigator>
      <last_name>Claudio Graiff, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant'Anna</name>
      <address>
        <city>Como</city>
        <state>CO</state>
        <zip>22020</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Monica Giordano, MD</last_name>
    </contact>
    <investigator>
      <last_name>Monica Giordano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Ospedale S.Martino</name>
      <address>
        <city>Genova</city>
        <state>GE</state>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Sobrero, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Polo Oncologico Vito Fazzi</name>
      <address>
        <city>Lecce</city>
        <state>LE</state>
        <zip>73100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Silvana Leo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo di Monza,</name>
      <address>
        <city>Monza</city>
        <state>MB</state>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Marina Cazzaniga, MD</last_name>
      <phone>+39 039 2339575</phone>
    </contact>
    <investigator>
      <last_name>Marina Cazzaniga, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Legnano</city>
        <state>MI</state>
        <zip>20025</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Sergio Fava, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Paolo</name>
      <address>
        <city>Milano</city>
        <state>MI</state>
        <zip>20142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Daris Ferrari, MD</last_name>
    </contact>
    <investigator>
      <last_name>Daris Ferrari, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico</name>
      <address>
        <city>Modena</city>
        <state>MO</state>
        <zip>41142</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>AUSL di Piacenza</name>
      <address>
        <city>Piacenza</city>
        <state>PC</state>
        <zip>29100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Luigi Cavanna, MD</last_name>
      <phone>+39 0523 302697</phone>
      <email>l.cavanna@ausl.pc.it</email>
    </contact>
    <investigator>
      <last_name>Luigi Cavanna, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>ULSS15 di Camposampiero/Cittadella</name>
      <address>
        <city>Camposampiero</city>
        <state>PD</state>
        <zip>35012</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Morabito, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaluiera Universitaria</name>
      <address>
        <city>Parma</city>
        <state>PR</state>
        <zip>43126</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesca Negri, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S.Salvatore</name>
      <address>
        <city>Pesaro</city>
        <state>PS</state>
        <zip>61100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>IRCCS F.S. Maugeri</name>
      <address>
        <city>Pavia</city>
        <state>PV</state>
        <zip>27100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Antonio Bernardo, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Ospedale Civile</name>
      <address>
        <city>Vigevano</city>
        <state>PV</state>
        <zip>27029</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedale San Carlo</name>
      <address>
        <city>Potenza</city>
        <state>PZ</state>
        <zip>85100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Domenico Bilancia, MD</last_name>
    </contact>
    <investigator>
      <last_name>Domenico Bilancia, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera</name>
      <address>
        <city>Ravenna</city>
        <state>RA</state>
        <zip>48121</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>A.O. S.Maria Nuova - IRCCS</name>
      <address>
        <city>Reggio Emilia</city>
        <state>RE</state>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Chiara Banzi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Azienda Policlinico Umberto I</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00161</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrico Cortesi, MD</last_name>
    </contact>
    <investigator>
      <last_name>Enrico Cortesi, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. C√† Foncello</name>
      <address>
        <city>Treviso</city>
        <state>TV</state>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Monica Ramello, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Casa di Cura di Poliambulanza, Via Bissolati 57</name>
      <address>
        <city>Brescia</city>
        <zip>25100</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Alberto Zaniboni, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. Careggi-Universit√†, Viale Pieraccini, 17</name>
      <address>
        <city>Firenze</city>
        <zip>50139</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Francesco Di Costanzo, MD</last_name>
      <role>Sub-Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>INT-IRCCS Fondazione G.Pascale</name>
      <address>
        <city>Napoli</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Massimo Montano, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario Campus Bio-Medico</name>
      <address>
        <city>Roma</city>
        <zip>00128</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A.Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Carlo Barone, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>A.O. S.Giovanni Calabita Fatebenefratelli</name>
      <address>
        <city>Roma</city>
        <zip>00186</zip>
        <country>Italy</country>
      </address>
    </facility>
    <status>Active, not recruiting</status>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>December 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>January 14, 2014</study_first_submitted>
  <study_first_submitted_qc>January 21, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 23, 2014</study_first_posted>
  <last_update_submitted>December 15, 2015</last_update_submitted>
  <last_update_submitted_qc>December 15, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 16, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>pancreatic cancer</keyword>
  <keyword>locally advanced</keyword>
  <keyword>unresectable cancer</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Paclitaxel</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Albumin-Bound Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

